Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02701283 · ClinicalTrials.gov registry record · NA

Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

A NA study of Aortic Valve Stenosis, sponsored by Medtronic Cardiovascular.

Active
Registry status
NA
Development phase
2,223
Enrollment target
20
Study locations

NCT02701283 is a NA study of Aortic Valve Stenosis that is active but no longer recruiting, run by Medtronic Cardiovascular. The registered enrollment target is 2,223 participants, above the 969-participant average among 30 other Aortic Valve Stenosis trials with a reported enrollment target (129% higher). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02701283, a NA study of Aortic Valve Stenosis, is active but no longer recruiting, sponsored by Medtronic Cardiovascular.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
2,223 participants
Enrollment target
20
Study locations

Study Summary

The study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or disabling stroke at two years is noninferior to SAVR in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR. The purpose of the expanded use addendum to the Medtronic TAVR in Low Risk Patients Trial protocol is to conclude the randomized phase of the trial and initiate the single-arm, non-randomized, continued access phase of the trial.

Conditions Studied

Interventions

  • DEVICE Medtronic Transcatheter Aortic Valve Replacement Systems
  • DEVICE Surgical Aortic Valve Replacement (SAVR)

Study Locations (20)

California

  • Scripps Memorial Hospital La Jolla - La Jolla
  • University of Southern California University Hospital - Los Angeles
  • El Camino Hospital - Mountain View
  • Mercy General Hospital - Sacramento
  • Los Robles Hospital & Medical Center - Thousand Oaks

Florida

  • Morton Plant Hospital - Clearwater
  • Delray Medical Center - Delray Beach
  • HealthPark Medical Center - Fort Myers
  • University of Miami Hospital - Miami
  • Tallahassee Research Institute, Inc. - Tallahassee

Arizona

  • Abrazo Arizona Heart Hospital - Phoenix

Colorado

  • University of Colorado Hospital - Aurora

Connecticut

  • Yale New Haven Hospital - New Haven

Georgia

  • Piedmont Atlanta Hospital - Atlanta

Illinois

  • Loyola University Medical Center - Maywood

Indiana

  • Saint Vincent Heart Center of Indiana - Indianapolis

Trial Details

FieldValue
Enrollment Target 2,223 participants
Start Date 2016-03
Est. Completion 2029-06
Phase NA

Sponsor

Medtronic Cardiovascular

44 total trials

What the Registry Record Tells You About NCT02701283

The ClinicalTrials.gov registry entry for NCT02701283 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 2,223 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 969-participant average among 30 other Aortic Valve Stenosis trials with a reported enrollment target (129% higher). The listed sponsor is Medtronic Cardiovascular, which has 44 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Aortic Valve Stenosis appearing as the primary indexed condition, and to 2 interventions - of which Medtronic Transcatheter Aortic Valve Replacement Systems is the first listed.

NCT02701283 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT02701283 about?

NCT02701283 is a clinical study titled "Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients". The study objective is to demonstrate that the safety and effectiveness of the Medtronic TAVR system as measured by rates of all-cause mortality or disabling stroke at two years is noninferior to SAVR in the treatment of severe aortic stenosis in subjects who have a low predicted risk of operative m...

What is the current status of trial NCT02701283?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 2,223 participants. The study started on 2016-03. Estimated completion is 2029-06.

What conditions does trial NCT02701283 study?

This clinical trial studies the following conditions: Aortic Valve Stenosis.

What interventions are being tested in trial NCT02701283?

The interventions under investigation include: Medtronic Transcatheter Aortic Valve Replacement Systems (DEVICE), Surgical Aortic Valve Replacement (SAVR) (DEVICE).

Who is sponsoring clinical trial NCT02701283?

This trial is sponsored by Medtronic Cardiovascular, which has 44 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02701283 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Aortic Valve Stenosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.